Intracellular Phenotypic Screening
US-2015346192-A1 · Dec 3, 2015 · US
Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
US9709552B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9709552-B2 |
| Application number | US-201514920612-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2015 |
| Priority date | Mar 23, 2007 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A monoclonal antibody that specifically binds to and inhibits expression or intracellular signaling of long-form BLT2 in a lung cell or immune cell. 2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is used for the treatment of asthma. 3. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutical carrier. 4. A kit for the treatment of asthma, the kit comprising the monoclonal antibody of claim 1 . 5. The kit of claim 4 , wherein the antibody selectively reduces the expression or intracellular signaling of long-form BLT2 to the patient while the expression or intracellular signaling of short-form BLT2 is not disrupted. 6. The kit of claim 4 , wherein the antibody specifically binds long-form BLT-2 in the region set forth by amino acids 1-31 of SEQ ID NO: 3. 7. The kit of claim 4 , wherein the antibody specifically binds long-form BLT-2 in the region set forth by amino acids 14-27 of SEQ ID NO: 3.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
involving cells · CPC title
interfering nucleic acids [NA] · CPC title
Double-stranded nucleic acids or oligonucleotides · CPC title
Special therapeutic applications · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9709552B2 cover?
- The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
- Who is the assignee on this patent?
- Korea Univ Res & Business Found, Univ Korea Res & Bus Found
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5023. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).